Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — 3 Marijuana Companies Close Their Doors in Colorado Over Liver Issues

Three businesses tied to the creation and sale of a marijuana-based sleep aid are shutting down their operations in Colorado after reaching a settlement and financial penalty that ends a lawsuit brought by the state.

The businesses, Nuka Properties LLC, Nuka Enterprises LLC, and Sima Sciences LLC, were behind the “1906” brand of products sold in Colorado since 2016. One of their best-known products was “Midnight Drops,” a pill made from cannabis combined with other plant-based ingredients.

According to state officials, problems with the product began surfacing in 2020, when consumers started filing complaints. In 2023, the state’s Department of Public Health and Environment and the Department of Revenue’s Marijuana Enforcement Division issued warnings to the public about health concerns linked to “Midnight Drops.”

The notice stated that earlier batches of “Midnight Drops,” produced before March 2022, contained an herbal ingredient called Corydalis, which could potentially cause liver damage. While research on Corydalis is limited, state officials said it raised enough concern to alert the public.

Later versions of the product were also flagged. State investigators found those pills included an extract from the Stephania plant containing L-THP, a compound also linked to signs of liver injury. The notice stated that users showed elevated liver enzyme levels, an early indicator of possible liver problems.

The notice stated that the companies had agreed to discontinue “Midnight Drops” and pull remaining stock from retailers. However, according to the attorney general’s office, the firms did not follow through. Instead, they allegedly continued producing and selling the capsules. Officials also accused the companies of failing to thoroughly research the safety of the herbal additives or properly inform stores about the risks.

The legal battle concluded last week with a settlement. The companies behind the 1906 line agreed to shut down their Colorado operations and pay a $400,000 fine. The agreement does leave open the possibility of resuming business at a later time if certain conditions are satisfied, though the state has not disclosed what those conditions are or how long they would remain in effect.

In addition, the settlement sets the stage for further financial consequences if the firms do not comply with the terms. Altogether, fines could climb as high as $1 million.

This case highlights a broader trend of regulators at both the federal and state levels penalizing companies that promote products with unsupported claims about health benefits.

The case also highlights why it is important to open legal marijuana markets where licensed companies, such as SNDL Inc. (NASDAQ: SNDL), are allowed to operate. Their products can undergo rigorous testing and any anomaly found can be addressed through product recalls or sanctioning the offending firms, as happened to the trio in Colorado. In this way, public health can be protected while also allowing adults who choose to consume products to do so safely.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — DOJ Urges Federal Court to Reject Suit Challenging DC Cannabis Sales Ban

The U.S. Department of Justice (DOJ) has asked a federal court to dismiss a case filed by a hemp company in Washington, D.C. The company, Capitol Hemp, is challenging restrictions from Congress that block local officials from setting up and overseeing a legal cannabis market in the District.

The DOJ submitted a motion to dismiss, arguing that the case should not move forward for procedural reasons.

Capitol Hemp wanted the court to declare that a congressional budget rider does not stop the city from creating a regulatory framework for hemp sales. The DOJ disagreed, saying the company has no legal standing to bring the case. According to the department, the suit is essentially a roundabout attempt to challenge federal law without directly confronting it.

In its filing, the government said the company’s alleged injuries—ongoing litigation against them and supposed confusion on the part of D.C. officials—do not meet the standard for standing. The department added that neither Congress’s appropriations law nor any U.S. action directly links those issues.

At the heart of the suit is the “Harris rider,” a provision named after Representative Andy Harris of Maryland. Since 2014, the rider has barred Washington, D.C., from using its local budget to establish a regulated cannabis market. The restriction has been renewed repeatedly, including in the most recent appropriations bills.

Capitol Hemp argues that the wording of the rider is unconstitutionally vague, as it uses the phrase “tetrahydrocannabinol derivative,” which, the company says, is undefined in federal law and overly broad. They contend this uncertainty makes it impossible for the District to know which substances it can regulate under its own laws.

The DOJ countered that even if the court made the declaration requested by Capitol Hemp, it would not require D.C. to pass laws the company wants. DOJ also argued that the lawsuit is built only on the Declaratory Judgment Act, which allows courts to issue rulings but does not itself create a cause of action. Without a genuine legal dispute between the parties, the government said, any ruling would amount to an advisory opinion.

While the DOJ avoided addressing the larger debate over whether D.C. should be allowed to regulate cannabis sales, the case highlights growing tension nationwide.

Lawmakers at both state and federal levels have been taking a closer look at THC-infused hemp products. Many of these products have become widely available due to gaps left by the 2018 Farm Bill. Critics say these products pose health risks since they are rarely tested for safety and are often sold to young people without restrictions.

The cannabis industry, including firms like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), will be watching how this lawsuit proceeds and assessing the implications of the ruling made by the federal court.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — OB/Gyn Association Calls for Universal Screening, Discourages Cannabis Use by Expectant Mothers

The American College of Obstetricians & Gynecologists (ACOG) has released new recommendations urging people to avoid marijuana during pregnancy and breastfeeding. The group also recommends that doctors regularly ask patients about marijuana throughout their pregnancy journey so they can better address possible risks.

Marijuana use has grown significantly among pregnant women in the U.S., a trend linked to changing laws and greater social acceptance. In response, ACOG developed the new guidelines to provide healthcare professionals with research-based strategies for counseling and reducing use.

According to a 2019 National Institute on Drug Abuse study of more than 450,000 women between 2002 and 2017, cannabis use during pregnancy more than doubled in that time.

Dr. Amy Valent, an obstetrician-gynecologist at Oregon Health and Science University and contributor to the new guidelines, said that normalization often leads people to underestimate risks. She noted that while cannabis hasn’t been definitively tied to birth defects, that alone does not make it safe for pregnancy.

Recent studies show that cannabinoid receptors form in a fetus within the first trimester and that THC, the primary psychoactive element in marijuana, can cross the placenta and enter breast milk. This exposure has been linked with poor outcomes such as NICU admissions, low birth weight, and, in some cases, higher risks of perinatal death. Long-term effects may also include developmental challenges such as attention problems, memory issues, or learning difficulties.

Although it is difficult to measure exactly how much cannabis leads to these outcomes, experts stress that the safest approach is to avoid use altogether.

The updated guidance also stresses how providers should approach screening. Biological testing, such as urine or hair samples, has historically led to biased treatment of ethnic and racial minority groups, and ACOG strongly advises against using those methods. Instead, open conversations and patient self-reporting are encouraged.

Doctors are encouraged to ask permission before bringing up the subject, keeping the tone nonjudgmental and focused on health rather than punishment.

The recommendations also acknowledge the complexity of state laws on drug testing during pregnancy, which can involve child protection services. ACOG urges providers to understand local regulations while still fostering a safe and honest space for patients.

According to ACOG, many individuals turn to cannabis to manage pregnancy-related nausea, anxiety, or stress. However, doctors suggest discussing other options that may ease symptoms, such as small dietary changes, light exercise, or safe medications. Valent noted that personalized care is key, since every patient’s situation is different.

Medical marijuana companies, such as Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), could also increase their consumer education programs so that individuals make informed decisions when choosing to use marijuana products while pregnant.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Does Marijuana Prohibition at the Federal Level Prevent Employee Unionization?

A marijuana business in Michigan is arguing that federal labor laws should not apply to marijuana employees since cannabis remains illegal under U.S. law in an attempt to block unionization.

The company, Exclusive Brands, based in Ann Arbor, recently made this case to the National Labor Relations Board (NLRB). If the board accepts the argument, it could weaken protections for workers in the fast-growing $32 billion cannabis market. Observers say this could be the first time a marijuana company has used federal prohibition as a reason to block union efforts.

For years, the NLRB has recognized cannabis employees’ rights under the National Labor Relations Act (NLRA). Reversing that stance would mean overturning its own precedent. Lauren McFarran, a former NLRB chair, described such a shift as a major departure. Still, some experts believe a Trump-era board could be open to such a move, given the administration’s record of limiting worker protections.

At the moment, the NLRB cannot act because it lacks the quorum needed to issue decisions. Until new appointments are made, labor disputes fall under state law, leaving cannabis workers and employers facing a confusing mix of rules depending on where they operate.

Tensions are already high in Michigan, where eight employees from Exclusive Brand have been on strike since late August. They voted to join the United Food and Commercial Workers union, but the company has refused to recognize their choice. Budtender Emily Hull, part of the organizing team, accused the company of cutting hours in retaliation against outspoken staff. According to Hull, Exclusive has also ignored attempts to negotiate.

Josh Leadford, the company’s attorney, filed a petition with the NLRB in early August. His filing claimed that because cannabis is classified as a Schedule I drug, neither Exclusive nor the union can seek protection or enforcement through the board. Notably, the petition did not cite prior case law. A hearing has yet to be scheduled.

Historically, even GOP-appointed panels have agreed that the NLRA applies to marijuana businesses. But if the NLRB remains in limbo, states may step in. Some states, such as California, Massachusetts, and New York, allow workers to appeal to state labor boards if the federal board cannot act. In conservative states with weaker labor regulations, however, cannabis companies might benefit.

Marijuana employees already face gaps in protection. Federal law excludes agricultural workers from the NLRA, which means many cultivation staff are left out unless their state has its own laws, as in California. Unions gained traction in the industry under Biden’s administration, with Arizona seeing its first agricultural unionization in decades.

However, major operators like Green Thumb and Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) have fought hard against union efforts in both the courts and before the NLRB.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Cannabis Firms in Delaware Can Now Transfer to Another County

Delaware’s cannabis commissioner has stated that marijuana license holders can now request to transfer their permits across Delaware’s three counties. This change opens the door for companies to relocate from areas with stricter rules, like Sussex County, to places where operating may be easier.

Speaking with Spotlight Delaware, Commissioner Joshua Sanderlin explained that the move overturns a rule put in place by the previous commissioner. The update comes after Sussex County and several municipalities introduced regulations in 2024 that left cannabis shops confined to very limited parts of the region.

Lawmakers tried to address the issue by passing Senate Bill 75 which aimed to reduce counties’ control over cannabis businesses. However, Governor Matt Meyer vetoed the measure, saying it stripped local governments of authority without offering them adequate support.

Sanderlin stressed that his office’s decision was not a direct response to the governor’s veto. Instead, it followed multiple requests from business owners who wanted flexibility in where they could operate. As someone who previously worked in the industry, he noted that his goal is to regulate fairly while also supporting license holders as partners rather than obstacles.

It’s still early to determine how the change will affect where businesses set up shop, but Sanderlin expects to see some movement toward New Castle and Kent Counties. At the same time, he believes the industry will eventually balance out across the state as businesses naturally gravitate toward financially sustainable locations.

Last year, Delaware issued 125 cannabis licenses but under the old rules, each one was tied to a specific county. That system, designed by Sanderlin’s predecessor Rob Coupe, was intended to guarantee fair distribution across the state. With the new rule, companies can apply to move their permits if they have trouble securing property in their assigned county.

One transfer has already been approved, allowing a manufacturer to relocate from New Castle to Sussex County after finding a workable site. He said more requests will be considered, as long as business owners present a solid relocation plan.

Sussex County has some of the toughest zoning rules, including a three-mile buffer between cannabis shops and schools or other sensitive locations. New Castle’s buffer is 1,000 feet, while Kent has none, though dispensaries there must be in commercial zones.

Business owners say the new flexibility gives them more options, particularly after SB 75 was vetoed. Sussex license holder Derro Smith, who runs a micro-cultivation business, said he would strongly consider moving his operation since his county has some of the toughest restrictions in the state.

Marijuana companies like Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) operating in other legal markets will be watching how the changes made in Delaware enable adults who choose to consume cannabis get improved access to licensed outlets over the coming months and years.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — US Congressional Committee to Conduct Hearing This Week on Illegal Chinese Cannabis Operations

A Republican-led committee in Congress is set to hold a hearing on what some lawmakers are calling a Chinese “invasion” of the United States through illegal cannabis operations.

The House Oversight, Investigations, and Accountability subcommittee announced that it will hold the hearing on September 18. Details about the specific agenda or the witnesses have not been released.

The issue of foreign-linked cannabis grows has drawn growing attention in Congress. Earlier this year, a report attached to the Commerce, Justice, Science, and Related Agencies spending bill instructed federal agencies to probe illegal cannabis cultivation across the U.S. Lawmakers specifically asked investigators to examine potential links to Chinese criminal networks or even ties to the Chinese government.

In 2024, Senator Chuck Grassley stated that illegal marijuana operations with Chinese connections were spreading across the country. He highlighted Oklahoma in particular, pointing out that thousands of state-licensed medical cannabis businesses had been flagged for questionable activity with suspected ties to China.

Similarly, Senator Susan Collins has repeatedly pressed federal officials about marijuana operations in her state that she believed to have connections to China.

The growing attention has also been used by prohibitionist organizations to push their arguments. In July, the Smart Approaches to Marijuana (SAM) group released an advertisement warning that moving forward with marijuana rescheduling could strengthen Chinese cartels.

The cannabis industry itself has faced missteps over the matter. In 2023, a major lobbying organization apologized for sending Senate leaders a letter on a bipartisan marijuana banking measure that made what it later admitted were “inappropriate” claims about Chinese investments, which the group said were included in a misguided push to influence amendments.

The timing of the upcoming House hearing is noteworthy, as it coincides with major developments in federal cannabis policy. Stakeholders and advocates are awaiting President Trump’s decision on whether to move marijuana from Schedule 1 to Schedule 3 under the Controlled Substances Act, a shift that would mark a significant change in how the government regulates the drug. The reclassification effort began under the Biden administration but has stalled since January 2025.

Meanwhile, the House Appropriations Committee recently advanced a spending measure designed to prevent the Department of Justice (DOJ) from changing cannabis’ classification. The House Oversight &Government Reform Committee also advanced legislation to roll back a Washington, D.C. law that expanded expungements for cannabis possession cases.

The broader marijuana industry, including the likes of Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), will be watching how the debates surrounding marijuana reclassification in Washington progress.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — California Lawmakers Send Bill Seeking to Halt Cannabis Tax Hikes to Governor

A measure to temporarily stop a recent tax hike on cannabis products in California has cleared the legislature and now awaits the governor’s decision.

The Assembly voted unanimously, 57-0, to accept amendments made in the Senate to the bill by Assemblymember Matt Haney. With that vote, the measure now heads to Governor Gavin Newsom, who has until October 12 to either sign or reject it.

If enacted, the bill would stop the increase in cannabis excise taxes for five years. Haney said the change is designed to give relief to an industry already dealing with high costs, reversing what he called an “unprecedented” 25% increase. Lawmakers from both parties have strongly backed the measure throughout the process.

One of the changes approved in the Senate pushes back the starting date to October rather than having the pause take effect immediately. The tax hike took effect in July, following state officials’ announcement in June that the marijuana excise tax would increase from 15% to 19%. At the time, supporters of the industry had hoped that ongoing budget discussions would include a freeze similar to Haney’s measure, but those talks fell short.

Although Newsom and Assembly Speaker Robert Rivas supported including a freeze in the budget process, Senate leader Mike McGuire reportedly opposed the move, leaving Haney to continue advancing his separate bill.

Haney’s measure originally would have locked in the lower 15% rate until 2030, with the California Department of Tax and Fee Administration (CDTFA) adjusting rates afterward every two years. Regulators would have been required to set tax levels to generate revenue comparable to what the state used to collect from the discontinued cultivation tax, but not above 19%.

The Senate Appropriations Committee later scaled back that timeline, shortening the period at the lower rate and adding requirements for annual reporting. Under the revised bill, the CDTFA, working in conjunction with the Finance Department, must determine tax adjustments annually.

They are tasked with estimating how much revenue the old cultivation tax would have generated and then setting the excise rate to raise a similar amount from retail cannabis sales.

The law’s stated purpose is to provide immediate financial relief for marijuana operators. To measure whether the change is effective, CDTFA will need to submit annual reports to the Legislature starting in December 2026, outlining gains or losses in tax revenue compared to expectations.

Separately, the Senate Appropriations Committee recently advanced another bill to regulate hemp-derived cannabinoids in California. That legislation would bring hemp-based products into the state’s cannabis framework, prohibit synthetic cannabinoids, and clarify rules for hemp items such as topical salves. The same committee also backed a measure allowing licensed cannabis microbusinesses to ship products directly to patients.

Most likely, other licensed firms like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) operating in other states would appreciate any efforts taken to provide some relief from the heavy tax load that they carry.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Texas Lt. Governor Releases Statement on His Disagreement with THC Ban Veto

Texas Lieutenant Governor Dan Patrick has issued a statement criticizing Governor Greg Abbott’s recent executive order on THC, saying it creates the impression that the state has endorsed the existing THC market.

Patrick stated that his dispute with the governor is not personal but centered on policy. He noted that while he and Abbott have worked together on many issues, they remain far apart on THC regulation.

According to Patrick, the order has been widely interpreted by the hemp and THC industry as a green light from the state. He pointed to public statements from business groups celebrating the decision as a major victory, arguing it legitimizes products that remain dangerous and often mislabeled.

“These are the same companies that have been marketing to minors and opening shops near schools,” Patrick said. He added that many of the products on the shelves are still illegal and, in some cases, carry ingredients not disclosed to buyers.

He warned that the governor’s action could pave the way for recreational cannabis use, despite Abbott’s repeated claims that legalization is not on the table. He emphasized that the Legislature has never voted to approve recreational cannabis. Instead, he said businesses have exploited loopholes in hemp laws to flood the market with high-potency products, now available in thousands of stores across Texas.

The lieutenant governor noted that Senate Bill 3, passed earlier in the year, would have banned such products outright, but the measure was vetoed. He said only a full ban can protect children since age limits on alcohol and tobacco have not prevented underage use. He also cited undercover police footage from Dallas showing smoke shop employees cautioning customers that overdosing on certain THC products could be deadly.

Patrick explained that during a special session, state leaders tried but failed to reach an agreement on safe limits for THC potency, serving size, and retail sales. Without clarity on those points, he said, lawmakers could not support moving forward.

He further argued that the governor’s order leaves major gaps. It does not stop the sale of synthetic variants such as Delta-8 or Delta-10, nor does it restrict the sale of potent Delta-9 products. He also faulted the order for allowing stores to remain near schools and for leaving enforcement responsibilities to already stretched law enforcement agencies.

Patrick further rejected claims in the order that states cannot ban THC under federal law. He pointed to multiple federal court rulings confirming states’ authority to impose bans and added that Congress is currently considering a nationwide prohibition on consumable THC.

The lieutenant governor closed his statement by reaffirming his support for the state’s Compassionate Use Program, which allows doctors to prescribe THC for medical purposes, as well as for legal CBG and CBD products. But he warned against what he sees as a path toward broader legalization. “We do not want to follow Colorado’s example,” he said, adding that he remains open to further discussions with the governor.

The debates surrounding the way to regulate hemp-sourced THC products in different jurisdictions will be closely watched by marijuana companies like Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) as it could have diverse implications for the legal marijuana industry.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Illinois Could Offer Solutions to What Happens if Holders of Social Equity Licenses Die

The U.S. legal marijuana market has been operating for more than a decade, and new challenges are beginning to surface that lawmakers did not anticipate when drafting regulations for the multibillion-dollar industry.

One issue currently grabbing attention in Illinois is what should happen if the holder of a cannabis social equity license passes away. For advocates of equity programs, the bigger question is whether the rules should ensure that ownership remains in the hands of people and communities that were harmed by decades of marijuana prohibition.

The matter recently gained attention after John Rushing, the licensee behind three Cookies-branded dispensaries in Illinois, passed away in December. Rushing was a Vietnam veteran and longtime resident of Palatine, Chicago. His company, Project Equity Illinois, had been awarded three retail permits in 2022. The licenses allowed the opening of Cookies shops in Pontoon Beach, Bloomington, and Peoria. Each store later received a $240,000 forgivable grant from the state.

The uncertainty now is whether those permits can transfer to his heirs or whether they must remain in the hands of someone who independently qualifies under Illinois’ social equity rules. Current law does not clearly spell this out, and regulators have avoided direct comment, pointing only to the existing statutes.

Public records confirm Rushing held the licenses, but state law provides only vague direction on how succession works if the original permit holder dies. Some observers argue that nothing prevents the permits from being sold, even to buyers who do not meet social equity qualifications.

This isn’t the first time death has complicated cannabis licensing in Illinois. When recreational sales began in 2020, some applicants passed away before their licenses were granted, which automatically voided those applications. Rushing’s case, however, is the first widely known instance of a license holder dying after the dispensaries were already operational.

Illinois’ social equity program is meant to repair some of the harm caused by decades of cannabis criminalization, especially for communities heavily targeted by drug laws. However, its requirements are looser compared to some other states. An applicant may qualify if they have lived in an area designated as disproportionately impacted, if they or a close family member have a marijuana-related conviction, or even through employees if a business has enough qualifying workers.

Experts question how long such programs will remain in place. Robert Silverman, a professor at the University of Buffalo, noted that equity permits were always intended as a temporary form of restitution. As fewer people meet the criteria over time, states may eventually decide that the special licenses are no longer needed and revert to standard business permits instead.

Cannabis firms around the country, such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF), will be watching how Illinois resolves the issue of an existing social equity license after its holder passes on. This decision could set a precedent that other states take a leaf from when handling a similar situation.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Nebraska Commission Heeds Governor’s Request and Sets Medical Marijuana Plant Limit

Nebraska’s Medical Cannabis Commission will restrict the number of plants medical growers can cultivate, setting the cap at 1,250 flowering cannabis plants per operation. The move followed pressure from Governor Jim Pillen, who stated that the new program must have firm boundaries before he approved emergency guidelines.

In a letter to the commission, the governor noted that without such a restriction, the risk of excess production could lead to illegal sales and undermine regulation. He indicated he would back the rest of the proposal if the adjustment were included.

The commission recently announced that it will authorize only four licenses for cultivators, with applications due by September 23 and licensing expected to start October 1. The discussion over limits was guided by Bo Botelho, legal counsel for the state’s Health and Human Services Department.

When drafting the initial framework, Botelho used Missouri’s program, which allows cultivation for both medical and recreational markets. His early suggestions were far lower than Missouri’s thresholds: 200 plants indoors, 300 in greenhouses, 500 outdoors, and 200 for mixed setups. He admitted the figures were only placeholders and not based on detailed calculations.

Commissioner Bruce Bailey led efforts to increase the limits, pointing out that not all plants survive or pass testing and that supply should be sufficient to meet patient demand. Estimates suggested that if about 1% of Nebraska’s population sought medical marijuana, roughly 20,000 patients could enroll. Using a simple formula of one plant for every two patients, the need would reach 10,000 plants statewide.

Other commissioners, including Lorelle Mueting and Kim Lowe, agreed that demand might not reach that level immediately but supported reviewing numbers later. Mueting noted that based on her research, 2,000 indoor plants could potentially produce adequate tinctures for approximately 2,300 patients annually. She, however, stressed that yields vary depending on how plants are grown.

Ultimately, Bailey suggested a single flat limit of 1,250 plants per cultivator, regardless of facility type. With four licensed growers, this would allow up to 5,000 plants in production at one time, with two harvests annually, meeting the target of 10,000 plants annually.

However, not everyone supports the restriction. Crista Eggers, who led the petition drive for medical marijuana legalization in the state, argues the program is being weakened before it even starts. Medical marijuana patients like Lia Post are urging the commission to recognize real medical needs rather than imposing what she sees as artificial restrictions.

The commission is set to meet again on September 30 at 1 p.m. Licensed cannabis companies like SNDL Inc. (NASDAQ: SNDL) operating in other markets will be watching how the market in Nebraska finally rolls out.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com